Perez RE - Search Results

1

JMJD2 promotes acquired cisplatin resistance in non-small cell lung carcinoma cells.

Duan L, Perez RE, Chastain PD 2nd, Mathew MT, Bijukumar DR, Maki CG. Duan L, et al. Among authors: perez re. Oncogene. 2019 Jul;38(28):5643-5657. doi: 10.1038/s41388-019-0814-6. Epub 2019 Apr 9. Oncogene. 2019. PMID: 30967636

2

Two 4N cell-cycle arrests contribute to cisplatin-resistance.

Shen H, Perez RE, Davaadelger B, Maki CG. Shen H, et al. Among authors: perez re. PLoS One. 2013;8(4):e59848. doi: 10.1371/journal.pone.0059848. Epub 2013 Apr 1. PLoS One. 2013. PMID: 23560058 Free PMC article.

3

The prolyl peptidases PRCP/PREP regulate IRS-1 stability critical for rapamycin-induced feedback activation of PI3K and AKT.

Duan L, Ying G, Danzer B, Perez RE, Shariat-Madar Z, Levenson VV, Maki CG. Duan L, et al. Among authors: perez re. J Biol Chem. 2014 Aug 1;289(31):21694-705. doi: 10.1074/jbc.M114.550038. Epub 2014 Jun 16. J Biol Chem. 2014. PMID: 24936056 Free PMC article.

4

Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1.

Duan L, Perez RE, Hansen M, Gitelis S, Maki CG. Duan L, et al. Among authors: perez re. Cancer Biol Ther. 2014;15(12):1600-12. doi: 10.4161/15384047.2014.961876. Cancer Biol Ther. 2014. PMID: 25482935 Free PMC article.

5

p53-regulated autophagy is controlled by glycolysis and determines cell fate.

Duan L, Perez RE, Davaadelger B, Dedkova EN, Blatter LA, Maki CG. Duan L, et al. Among authors: perez re. Oncotarget. 2015 Sep 15;6(27):23135-56. doi: 10.18632/oncotarget.5218. Oncotarget. 2015. PMID: 26337205 Free PMC article.

6

Modeling the Etiology of p53-mutated Cancer Cells.

Perez RE, Shen H, Duan L, Kim RH, Kim T, Park NH, Maki CG. Perez RE, et al. J Biol Chem. 2016 May 6;291(19):10131-47. doi: 10.1074/jbc.M116.724781. Epub 2016 Mar 28. J Biol Chem. 2016. PMID: 27022024 Free PMC article.

7

Crosstalk between the IGF-1R/AKT/mTORC1 pathway and the tumor suppressors p53 and p27 determines cisplatin sensitivity and limits the effectiveness of an IGF-1R pathway inhibitor.

Davaadelger B, Duan L, Perez RE, Gitelis S, Maki CG. Davaadelger B, et al. Among authors: perez re. Oncotarget. 2016 May 10;7(19):27511-26. doi: 10.18632/oncotarget.8484. Oncotarget. 2016. PMID: 27050276 Free PMC article.

8

The IGF-1R/AKT pathway has opposing effects on Nutlin-3a-induced apoptosis.

Davaadelger B, Perez RE, Zhou Y, Duan L, Gitelis S, Maki CG. Davaadelger B, et al. Among authors: perez re. Cancer Biol Ther. 2017 Nov 2;18(11):895-903. doi: 10.1080/15384047.2017.1345397. Epub 2017 Jul 11. Cancer Biol Ther. 2017. PMID: 28696156 Free PMC article.

9

p53 promotes AKT and SP1-dependent metabolism through the pentose phosphate pathway that inhibits apoptosis in response to Nutlin-3a.

Duan L, Perez RE, Chen L, Blatter LA, Maki CG. Duan L, et al. Among authors: perez re. J Mol Cell Biol. 2018 Aug 1;10(4):331-340. doi: 10.1093/jmcb/mjx051. J Mol Cell Biol. 2018. PMID: 29190376 Free PMC article.

10

DZNep represses Bcl-2 expression and modulates apoptosis sensitivity in response to Nutlin-3a.

Zhou Y, Perez RE, Duan L, Maki CG. Zhou Y, et al. Among authors: perez re. Cancer Biol Ther. 2018 Jun 3;19(6):465-474. doi: 10.1080/15384047.2018.1433500. Epub 2018 Mar 13. Cancer Biol Ther. 2018. PMID: 29394130 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

75 results

Search Page